OBJECTIVE: To systematically evaluate the effects of Huisheng oral liquid on coagulation function

efficacy and safety of patients with non-small cell lung cancer. METHODS: CNKI

Wanfang Data

CBM

VIP

PubMed

the Cochrane Library

Embase and Web of Science were retrieved to collect the randomized controlled trial of effects of Huisheng oral liquid on coagulation function

efficacy and safety of patients with non-small cell lung cancer（the study group was treated with Huisheng oral liquid combined with other treatment or Huisheng oral liquid; while the control group received other treatment） till Sept. 2021. Quality evaluation and data extraction of the included literature were performed

and RevMan 5.3 software was used for Meta-analysis. RESULTS: Totally 24 RCT were enrolled

including 1 783 patients（908 cases in the study group and 875 cases in the control group）. Meta-analysis showed that the elevated values of D-dimer level（SMD=-1.46

95%CI=-2.75--0.18

P=0.03）

fibrinogen（Fib） level（MD=-0.81

95%CI=-1.14--0.48

P<0.000 01） and platelet count（PLT）（MD=-82.91

95%CI=-147.72--18.11

P=0.01） in the study group were significantly lower than those in the control group

and the differences were statistically significant. There was no significant difference in prothrombin time（MD=-0.71

95%CI=-1.71-0.30

P=0.17） and activated partial prothrombin time（MD=3.67

95%CI=-15.15-22.48

P=0.70） between two groups. The objective response rate（RR=1.28

95%CI=1.09-1.51

P=0.003）

disease control rate（RR=1.15

95%CI=1.06-1.25

P=0.000 9） and improvement rate of KPS（RR=1.72

95%CI=1.39-2.13

P<0.000 01） in the study group were significantly better than those in the control group

the difference was statistically significant. There was no significant difference in the incidence of nausea and vomiting（RR=0.49

95%CI=0.20-1.20

P=0.12） and leukopenia（RR=0.59

95%CI=0.29-1.20

P=0.15） between two groups. CONCLUSIONS: Huisheng oral liquid may improve the coagulation function of patients with non-small cell lung cancer by reducing the levels of D-dimer

Fib and PLT. Meanwhile

it can improve the short-term clinical efficacy and quality of life of patients with non-small cell lung cancer

yet more high-quality clinical studies are needed to verify.